The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Hims & Hers faces a significant revenue risk, as the FDA’s decision could eliminate its ability to sell compounded GLP-1 medications. The potential ban on compounded semaglutide could result in a ...

One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

Truist analyst Jailendra Singh raised the firm’s price target on Hims & Hers to $39 from $24 and keeps a Hold rating on the shares after ...

This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

Hims and Hers Health Inc. (HIMS) produced sterling results on Feb. 24, spurring huge interest in HIMS call options trading.

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Dr. Kristen Kells, founder of Colorado Springs’ largest weight loss clinic, shared insights on GLP-1 drugs and explained why the Dr. Kells Method can offer better long-term ...

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...